急性脑干梗死采用尤瑞克林辅助治疗的临床疗效与药理分析
|
摘要
目的探究对急性脑干梗死患者实施尤瑞克林辅助治疗的效果,并解析其药理作用。方法 86例急性脑干梗死患者,根据治疗方法不同分为观察组与对照组,各43例。观察组应用阿司匹林加尤瑞克林治疗,对照组应用阿司匹林治疗。对比两组患者疗效、美国国立卫生研究院卒中量表(NIHSS)评分、炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平及不良反应发生情况。结果治疗前,对照组患者NIHSS评分为(30.30±2.28)分,观察组患者NIHSS评分为(30.24±2.25)分,对比差异无统计学意义(P>0.05);治疗后,对照组患者NIHSS评分为(23.42±2.36)分,观察组患者NIHSS评分为(21.02±1.02)分,两组患者NIHSS评分均低于本组治疗前,且观察组患者NIHSS评分低于对照组,差异均具有统计学意义(P<0.05)。观察组总有效率95.35%高于对照组的79.07%,差异具有统计学意义(P<0.05)。治疗前,对照组患者IL-6、TNF-α水平分别为(48.50±12.33)、(62.44±2.59)ng/ml,观察组患者IL-6、TNF-α水平分别为(48.46±12.30)、(62.36±2.65)ng/ml,对比差异均无统计学意义(P>0.05);治疗后,对照组患者IL-6、TNF-α水平分别为(29.78±2.95)、(30.30±2.15)ng/ml,观察组患者IL-6、TNF-α水平分别为(20.16±0.42)、(21.42±0.29)ng/ml,两组患者IL-6、TNF-α水平均低于本组治疗前,且观察组患者IL-6、TNF-α水平均低于对照组,差异均具有统计学意义(P<0.05)。治疗期间,对照组不良反应发生率为9.30%,观察组不良反应发生率为2.33%,对比差异无统计学意义(P>0.05)。发生不良反应的患者均经对症干预治疗后恢复。结论对急性脑干梗死患者实施尤瑞克林辅助治疗十分可行,效果较佳。
Objective To investigate the effect and pharmacological effect of urinary kallidinogenase for adjuvant treatment of acute cerebral infarction. Methods A total of 86 patients with acute cerebral infarction were divided by different treatment methods into observation group and control group, with 43 cases in each group. The observation group was treated with aspirin and urinary kallidinogenase, and the control group was treated with aspirin. Comparison were made on efficacy, National Institutes of Health Stroke scale(NIHSS), levels of inflammatory factors [interleukin-6(IL-6), tumor necrosis factor-α(TNF-α)] and occurrence of adverse reactions between the two groups. Results Before treatment, the control group had NIHSS score as(30.30±2.28) points, which was(30.24±2.25) points in the observation group, and the difference was not statistically significant(P>0.05). After treatment, the control group had NIHSS score as(23.42±2.36) points, which was(21.02±1.02) points in the observation group. Both groups had lower NIHSS score than those before treatment, and the observation group had lower NIHSS score than the control group. Their difference was statistically significant(P<0.05). The observation group had higher total effective rate as 95.35% than 79.07% in the control group, and the difference was statistically significant(P<0.05).Before treatment, the control group had IL-6 and TNF-α level respectively as(48.50±12.33) and(62.44±2.59) ng/ml, which were(48.46±12.30) and(62.36±2.65) ng/ml in the observation group. Their difference was not statistically significant(P>0.05). After treatment, the control group had IL-6 and TNF-α respectively as(29.78±2.95) and(30.30±2.15) ng/ml, which were(20.16±0.42) and(21.42±0.29) ng/ml in the observation group. Both groups had lower IL-6 and TNF-α than those before treatment, and the observation group had lower IL-6 and TNF-α than the control group. Their difference was statistically significant(P<0.05). During treatment,the control group had incidence of adverse reactions as 9.30% and the observation group had incidence of adverse reactions as 2.33%. Both groups had no statistically significant difference in incidence of adverse reactions(P>0.05). All the patients with adverse reactions recovered after symptomatic intervention. Conclusion Urinary kallidinogenase is feasible and effective for patients with acute cerebral infarction.
Objective To investigate the effect and pharmacological effect of urinary kallidinogenase for adjuvant treatment of acute cerebral infarction. Methods A total of 86 patients with acute cerebral infarction were divided by different treatment methods into observation group and control group, with 43 cases in each group. The observation group was treated with aspirin and urinary kallidinogenase, and the control group was treated with aspirin. Comparison were made on efficacy, National Institutes of Health Stroke scale(NIHSS), levels of inflammatory factors [interleukin-6(IL-6), tumor necrosis factor-α(TNF-α)] and occurrence of adverse reactions between the two groups. Results Before treatment, the control group had NIHSS score as(30.30±2.28) points, which was(30.24±2.25) points in the observation group, and the difference was not statistically significant(P>0.05). After treatment, the control group had NIHSS score as(23.42±2.36) points, which was(21.02±1.02) points in the observation group. Both groups had lower NIHSS score than those before treatment, and the observation group had lower NIHSS score than the control group. Their difference was statistically significant(P<0.05). The observation group had higher total effective rate as 95.35% than 79.07% in the control group, and the difference was statistically significant(P<0.05).Before treatment, the control group had IL-6 and TNF-α level respectively as(48.50±12.33) and(62.44±2.59) ng/ml, which were(48.46±12.30) and(62.36±2.65) ng/ml in the observation group. Their difference was not statistically significant(P>0.05). After treatment, the control group had IL-6 and TNF-α respectively as(29.78±2.95) and(30.30±2.15) ng/ml, which were(20.16±0.42) and(21.42±0.29) ng/ml in the observation group. Both groups had lower IL-6 and TNF-α than those before treatment, and the observation group had lower IL-6 and TNF-α than the control group. Their difference was statistically significant(P<0.05). During treatment,the control group had incidence of adverse reactions as 9.30% and the observation group had incidence of adverse reactions as 2.33%. Both groups had no statistically significant difference in incidence of adverse reactions(P>0.05). All the patients with adverse reactions recovered after symptomatic intervention. Conclusion Urinary kallidinogenase is feasible and effective for patients with acute cerebral infarction.
引文
[1]王志伟,邱峰,段枫,等.起病时头颅磁共振成像阴性的恶性眩晕三例并文献复习.中华内科杂志, 2015, 54(4):334-335.
[2]张永鑫,王建平,崔可飞,等.多奈哌齐对脑梗死模型小鼠室管膜下区神经发生相关营养因子表达的影响.中华行为医学与脑科学杂志, 2018, 27(11):961-965.
[3]陈红兵,李竹浩,刘刚,等.双侧脑干梗死患者临床影像学的特征和病因分析.中华老年心脑血管病杂志, 2016, 18(3):268-273.
[4]闫国平,臧大维,李欣慧,等.眼前庭诱发肌源性电位在急性脑干梗死中的应用.中华物理医学与康复杂志, 2015, 37(10):765-769.
[5]麦艺颖,戴萌,谢纯青,等.电视透视吞咽检查定量评价脑干梗死患者吞咽障碍特点的临床研究.中华物理医学与康复杂志, 2018, 40(2):87-90.
[6]晏玉奎,孙晓燕,刘泉坤,等.首次脑干梗死患者复发脑梗死的类型与风险分析.中华全科医师杂志, 2015, 14(9):703-706.
[7]姚雪华,陈雪珍,赵金凤,等.一例脑干梗死植物生存状态十年患者营养支持状况分析.中华现代护理杂志, 2016, 22(9):1319-1321.
[8]卢俏丽,姚连焕,胆迎,等.老年脑梗死患者心率变异性及其与神经功能缺损评分相关性研究.中华老年医学杂志, 2016,35(11):1155-1159.
[9]马得廷,王君霞,盛蕾,等.脑干急性梗死弥散加权成像的相关性分析研究.中华临床医师杂志(电子版), 2016, 10(3):321-324.
[10]王欣,曲松滨.急性脑梗死患者的窦性心率震荡现象.中华老年心脑血管病杂志, 2016, 18(4):419-420.
[11]崔自慧.尤瑞克林辅助治疗急性脑干梗死的疗效分析.中国实用神经疾病杂志, 2017, 20(9):119-121.
[12]畅怡,钱向阳,于存涛,等. Kommerell憩室合并主动脉弓降部动脉瘤的外科治疗.中华胸心血管外科杂志, 2018, 34(11):659-663.
[13]钟水生,胡琼力,李志刚,等.合并阻塞性睡眠呼吸暂停综合征的脑梗死患者血清皮质醇水平的测定.中华神经医学杂志,2018, 17(8):796-801.
[14]郑苏平,解林花,尚进,等.维持性血液透析患者脑梗死发生率及危险因素研究.中华老年心脑血管病杂志, 2018, 20(7):724-727.
[15]郭萍萍.急性脑干梗死采用尤瑞克林辅助治疗的临床疗效和药理解析.北方药学, 2017, 14(6):46-47.
[2]张永鑫,王建平,崔可飞,等.多奈哌齐对脑梗死模型小鼠室管膜下区神经发生相关营养因子表达的影响.中华行为医学与脑科学杂志, 2018, 27(11):961-965.
[3]陈红兵,李竹浩,刘刚,等.双侧脑干梗死患者临床影像学的特征和病因分析.中华老年心脑血管病杂志, 2016, 18(3):268-273.
[4]闫国平,臧大维,李欣慧,等.眼前庭诱发肌源性电位在急性脑干梗死中的应用.中华物理医学与康复杂志, 2015, 37(10):765-769.
[5]麦艺颖,戴萌,谢纯青,等.电视透视吞咽检查定量评价脑干梗死患者吞咽障碍特点的临床研究.中华物理医学与康复杂志, 2018, 40(2):87-90.
[6]晏玉奎,孙晓燕,刘泉坤,等.首次脑干梗死患者复发脑梗死的类型与风险分析.中华全科医师杂志, 2015, 14(9):703-706.
[7]姚雪华,陈雪珍,赵金凤,等.一例脑干梗死植物生存状态十年患者营养支持状况分析.中华现代护理杂志, 2016, 22(9):1319-1321.
[8]卢俏丽,姚连焕,胆迎,等.老年脑梗死患者心率变异性及其与神经功能缺损评分相关性研究.中华老年医学杂志, 2016,35(11):1155-1159.
[9]马得廷,王君霞,盛蕾,等.脑干急性梗死弥散加权成像的相关性分析研究.中华临床医师杂志(电子版), 2016, 10(3):321-324.
[10]王欣,曲松滨.急性脑梗死患者的窦性心率震荡现象.中华老年心脑血管病杂志, 2016, 18(4):419-420.
[11]崔自慧.尤瑞克林辅助治疗急性脑干梗死的疗效分析.中国实用神经疾病杂志, 2017, 20(9):119-121.
[12]畅怡,钱向阳,于存涛,等. Kommerell憩室合并主动脉弓降部动脉瘤的外科治疗.中华胸心血管外科杂志, 2018, 34(11):659-663.
[13]钟水生,胡琼力,李志刚,等.合并阻塞性睡眠呼吸暂停综合征的脑梗死患者血清皮质醇水平的测定.中华神经医学杂志,2018, 17(8):796-801.
[14]郑苏平,解林花,尚进,等.维持性血液透析患者脑梗死发生率及危险因素研究.中华老年心脑血管病杂志, 2018, 20(7):724-727.
[15]郭萍萍.急性脑干梗死采用尤瑞克林辅助治疗的临床疗效和药理解析.北方药学, 2017, 14(6):46-47.